People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure,
atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …

Aim To assess the relationship of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i),
glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i+ …

Despite continuous advances in both diagnosis and management, heart failure (HF) still
represents a major worldwide health issue. Recently, sodium-glucose co-transporter 2 …

The recently published randomized trials (RCTs) evaluating the effect of Sodium-glucose
cotransporter-2 inhibitors (SGLT2i) in heart failure with mildly reduced (HFmrEF) or …

Aims Glucagon-like peptide-1 receptor agonists (GLP1-ra) have shown to reduce
cardiovascular (CV) events in patients with diabetes, including heart failure (HF) …

Background It remains controversial whether sodium-glucose cotransporter-2 inhibitors
(SGLT-2is) are effective in treating heart failure with preserved ejection fraction (HFpEF) …

Diabetes mellitus is a metabolic disorder characterized by increased serum glucose due to
errors in insulin production or response. The prevalence of diabetes mellitus has continued …

In this issue of the journal, Dr Lip and co-workers aimed to compare the effectiveness and
safety for very low dose (VLD) non-vitamin K antagonist oral anticoagulants …

A rapidly expanding number of clinical trials are advancing clinical care in the field of
diabetes and chronic kidney disease (CKD). The American Diabetes Association (ADA) and …